Advances in prevention of respiratory syncytial virus infections.
Prober
C G
CG
Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California 94305-5208, USA.
Sullender
W M
WM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control; D017053:Infection Control; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016756:Immunoglobulins, Intravenous; D000069455:Palivizumab